Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives $30.33 Consensus PT from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been given an average rating of “Buy” by the twelve research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, eight have given a buy rating and three have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $32.1111.

Several analysts recently commented on DFTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday. Canaccord Genuity Group raised their target price on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Lifesci Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 14th. Royal Bank Of Canada increased their price target on Definium Therapeutics from $20.00 to $36.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Jones Trading began coverage on Definium Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $61.00 price objective on the stock.

Definium Therapeutics Trading Up 2.5%

Shares of NASDAQ:DFTX opened at $17.40 on Tuesday. Definium Therapeutics has a 12-month low of $4.70 and a 12-month high of $18.12. The company has a market capitalization of $1.71 billion, a PE ratio of -8.53 and a beta of 2.57. The business has a 50 day moving average of $13.16 and a two-hundred day moving average of $11.45. The company has a current ratio of 3.30, a quick ratio of 3.30 and a debt-to-equity ratio of 0.31.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). As a group, analysts forecast that Definium Therapeutics will post -1.35 EPS for the current year.

Insider Activity at Definium Therapeutics

In other news, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the sale, the insider owned 282,576 shares in the company, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Daniel Karlin sold 5,600 shares of the company’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the transaction, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This trade represents a 1.30% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 42,667 shares of company stock valued at $561,071. 2.26% of the stock is owned by company insiders.

Institutional Investors Weigh In On Definium Therapeutics

Several large investors have recently bought and sold shares of DFTX. Russell Investments Group Ltd. raised its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after acquiring an additional 2,003 shares during the last quarter. BIT Capital GmbH purchased a new stake in shares of Definium Therapeutics during the third quarter worth approximately $26,000. CWM LLC raised its stake in Definium Therapeutics by 67.4% in the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares during the last quarter. Fifth Third Bancorp lifted its holdings in Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after purchasing an additional 3,300 shares in the last quarter. Finally, Sound Income Strategies LLC purchased a new position in Definium Therapeutics in the 3rd quarter valued at $46,000. 27.91% of the stock is currently owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.